Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)

Study identification

• EU PAS number:
  EUPAS1000000519
• Study ID:
  1000000519
• Official title and acronym:
  Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Belgium

  European Union

  France

  Germany

  Greece

  Italy

  Netherlands

  Poland

  Spain

  Switzerland

  United Kingdom
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned: 01/04/2025

Actual: 09/04/2025

Study start date

Planned: 30/05/2025

Actual: 21/05/2025

Date of final study report

Planned: 25/10/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

UCB Biopharma SRL

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

Internal study ID: SPA002